Adaptive Designs in Clinical Trials Conference 2018

SMi Group9 - 10 April 2018, London, UK.
This year's agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug, medical device and therapy development.

Giving you a fresh take on this vital area of biopharma, the event will ride the wave of technology within the pharmaceutical industry, as we consider how the increasing use of smartphone apps and digital devices is changing the way trials run. Simultaneously, the event will also explore how adaptive designs are being used for the production of personalised medicines and personalised therapies.

Featured Speakers include:

  • James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
  • Alex Sverdlov, Director, Statistical Scientist, Novartis
  • Frank Fleisher, Principal Methodology Statistician, Boehringer-Ingelheim
  • Christine Fletcher, Executive Director Biostatistics, Amgen
  • Chris Harbron, Principal Statistical Scientist, Roche
  • Olivier Collignon, Biostatistician, European Medicines Agency
  • Beatrice Panico, Medical Advisor, MHRA
  • Corine Baayen, Senior Biostatistician, H.Lundbeck

Key Highlights

  • Explore the current industry outlook and evaluate the promises and challenges of digital technology use
  • Hear exciting case studies on enrichment designs and group sequential trials
  • Discover how big pharma companies are using Platform Trials and self-adapting priors to advance their adaptive clinical trials
  • Examine the use of adaptive clinical trials are used to produce targeted therapies
  • Learn from the latest regulatory perspectives from MHRA and EMA, including planning and assessing umbrella and basket trials

For further information and to register, please visit:
http://www.adaptivedesigns.co.uk

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...